Ranitidine: Overview and Applications

Ranitidine is an H₂ receptor antagonist, mainly used to inhibit gastric acid secretion and treat gastric ulcer, duodenal ulcer, reflux esophagitis and other digestive tract diseases. Its mechanism of action is by blocking H₂ receptors in gastric parietal cells, reducing gastric acid secretion, relieving symptoms and promoting ulcer healing. In terms of content structure, this article will introduce the pharmacological effects, clinical applications, precautions, manufacturers and market conditions of ranitidine in sequence, and finally summarize its actual value. Focus on its therapeutic efficacy and safety to avoid deviating from the topic.

Pharmacological effects and indications

Ranitidine significantly reduces gastric acid secretion by selectively inhibiting H₂ receptors in gastric parietal cells, and has a strong inhibitory effect on basal gastric acid and nocturnal gastric acid secretion. Its indications include: gastric ulcer, duodenal ulcer, Zollinger-Ellison syndrome (gastrinoma) and reflux esophagitis. Compared with first-generation H₂ receptor antagonists (such as cimetidine), ranitidine has a longer-lasting effect and fewer side effects. Clinical data shows that it can shorten ulcer healing time and effectively relieve symptoms such as heartburn and acid reflux.

Usage, dosage and precautions

The usual dosage for adults is 150mg/time, twice a day, or 300mg before bedtime. The course of treatment is usually 4-8 weeks. Patients with renal insufficiency need to reduce the dose. Common adverse reactions include headache, diarrhea, constipation, etc., but the incidence is low. It should be noted that long-term use may affect the absorption of vitamin B₁₂, and elderly patients should be monitored regularly. In addition, ranitidine interacts with certain drugs (such as ketoconazole), and the medication regimen needs to be adjusted as directed by your doctor.

Manufacturers and market conditions

The original drug of ranitidine was developed by GlaxoSmithKline (GSK) under the trade nameZantac. Many domestic pharmaceutical companies also produce generic drugs. Common brands include:

After 2020, due to the detection of NDMA (nitrosamine) impurities in some batches, many countries suspended the marketing of ranitidine. However, after process improvements, some manufacturers have resumed production.

Summary and Outlook

As a classic acid-suppressing drug, ranitidine was once a commonly used drug in gastroenterology because of its accurate efficacy and low price. Although it has been limited in recent years due to safety concerns, it still has value in short-term treatment. In the future, the production process needs to be further optimized to ensure drug safety, and new drugs such as proton pump inhibitors (PPIs) should be combined to provide patients with more comprehensive treatment options.

Quote sources:
1. "Chinese Pharmacopoeia" 2020 Edition
2. GlaxoSmithKline (GSK) drug instructions
3. Announcement from the National Medical Products Administration (NMPA)